ALFA Finder| Revenue growth | 12.3% YoY consolidated FY26; 21.3% YoY Q4 FY26. |
|---|---|
| Margins | Gross margin expanded 130bps in FY26 via product mix optimization. |
| Demand visibility | Strong; cumulative stent deployments surpassed ~11K units. |
| Management confidence | High; citing 21% sequential H1 to H2 growth in-line with guidance. |
Growth
FY26 Consolidated Revenue reached ₹1,875.3 Cr (up 12.3%); Consolidated PAT was ₹320.7 Cr (down 5.3% due to acquisition costs/subsidiary provisions).
Outlook
Guidance for FY27 patient enrollment in clinical trials; capex of ₹296 Cr in FY26; focused on Cardiology/Orthopaedics expansion.
Risks
Q4 EBITDA impacted by one-time regulatory and employee costs in subsidiaries; global supply chain and pricing challenges.
Earnings Call filed with BSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,672.10
- Market cap
- ₹16,949 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 53.2×Sector 54.5×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Earnings Call Transcript: Key Takeaways
Consolidated Q2 revenue rose 31%, but H1 organic growth was only 14%. Pendra Care is loss-making and Italy tenders are delayed. FY27 revenue guidance was reaffirmed and the standalone margin band raised.
- Call
- Guides 100% growth
Poly Medicure Other Announcement
Poly Medicure's board revised five governance policies and codes, including material subsidiary, materiality, related party transactions, and insider trading codes. The revised documents are published on the company website.
Poly Medicure Q2 FY27 Results: Net Profit ₹95.1 Cr, Up 3.6% YoY
Poly Medicure Ltd reported revenue from operations of ₹580.5 Cr (+30.8% YoY) and net profit of ₹95.1 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹95.1 Cr · +3.6% YoY
Poly Medicure Board Meeting Date
Poly Medicure will hold a board meeting on 05 November 2026 to consider unaudited results. Trading window stays closed until 07 November 2026.
Poly Medicure Other Announcement
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.